Active substanceStreptomycinStreptomycin
Similar drugsTo uncover
  • Streptomycin
    powder w / m 
  • Streptomycin
    powder w / m 
    BIOCHEMIST, OJSC     Russia
  • Streptomycin
    powder w / m 
    SYNTHESIS, OJSC     Russia
  • Dosage form: & nbsp: powder for solution for intramuscular injection
    Composition:
    One bottle contains: streptomycin sulfate (in terms of streptomycin) - 0.5 g and 1.0 g.

    Description:The powder is white or almost white. Hygroscopic
    Pharmacotherapeutic group:Antibiotic. Aminoglycoside
    ATX: & nbsp

    J.01.G.A   Streptomycins

    J.01.G.A.01   Streptomycin

    Pharmacodynamics:
    Antibiotic of a broad spectrum of action from the group of aminoglycosides. It is formed in the process of vital activity of radiant fungi of Streptomyces globisporus or other species of Streptomyces spp. At low concentrations, bacteriostatic action: penetrating into the microbial cell, binds to specific receptor proteins on the 30S subunit of the bacterial ribosome, disrupting the formation of the initiating complex "matrix RNA + 30S subunit of the ribosome," which leads to the disintegration of the polar bosomes, resulting in defects in reading information with DNA, defective proteins are synthesized, which eventually leads to a halt in the growth and development of the microbial cell. In higher concentrations streptomycin has a bactericidal effect (damages the cytoplasmic membrane, causing death of the microbial cell).
    Has a wide spectrum of antimicrobial action. It is active against Mycobacterium tuberculosis, the majority of Gram-negative bacteria (Escherichia coli, Klebsiella spp. (Including Klebsiella pneumoniae), Proteus spp., Salmonella spp., Shigella spp., Yersinia spp. (Including Yersinia pestis) , Brucella spp., Francisella tularensis, Haemophilus ducreyi, Haemophilus influenzae, Neisseria gonorrhoeae, Neisseria meningitidis, some Gram-positive microorganisms (Staphylococcus spp., Corynebacterium diphtheriae).
    Moderately active against Streptococcus spp. (including Streptococcus pneumoniae), Enterococcus spp.
    In combination with benzylpenpicillin or vancomycin streptomycin is effective in the treatment of endocarditis caused by Enterococcus faecalis or Streptococcus group of viridans.
    Stable in a slightly acidic environment, but easily destroyed in solutions of acids and alkalis with heating.
    Secondary resistance of bacteria develops rapidly.
    Streptomycin is inactive against anaerobic bacteria, the family. Spirochaeta ceae, Rickettsia spp., Pseudomonas aeruginosa.

    Pharmacokinetics:
    After intramuscular injection streptomycin quickly and completely absorbed from the injection site. The time to reach the maximum concentration in the blood is 0.5-1.5 hours, the maximum concentration in the blood after the / m administration is 1 g -25-50 μg / ml. The connection with plasma proteins is less than 10%.
    Distributed in all tissues of the body (except brain tissue), incl. in extracellular fluid, fluid abscesses, pleural effusion, in ascitic, pericardial, synovial, lymphatic and peritoneal fluids.High concentrations are created in the kidneys, liver, lungs; low - in bone and adipose tissue. The volume of distribution in adults is 0.26 l / kg, in children 0.2-0.4 l / kg, in newborns less than 1 week old and weighing less than 1500 g, up to 0.68 l / kg, less than 1 week and a body weight of more than 1500 grams - up to 0.58 l / kg, in patients with mucovidosis - 0.3-0.39 l / kg. It does not penetrate the intact blood-brain barrier. Penetrates through the placenta and into breast milk.
    Metabolism is not affected.
    The half-life period (T1 / 2) in adults is 2-4 hours, in newborns 5-8 hours, in older children 2.5-4 hours. The final T1 / 2 is more than 100 hours (release from the intracellular depot) . In patients with renal insufficiency, T1 / 2 varies depending on the degree of insufficiency - up to 100 h, in patients with mucoviscosis - 1-2 h, in patients with burns and hyperthermia may be shorter in comparison with the average values ​​due to elevated clearance. It is excreted by the kidneys (95%) unchanged by glomerular filtration.

    Indications:
    • tuberculosis of different localization, incl. tuberculous meningitis (as part of combination therapy);
    • venereal granuloma;
    • tularemia, brucellosis, plague;
    • bacterial endocarditis (only in combination with benzylpenicillin or vancomycin);
    • acute bacterial intestinal infections, urinary tract infections (after the sensitivity of the pathogen).

    Contraindications:
    Hypersensitivity (including other aminoglycosigns in the anamnesis), severe chronic renal failure with azotemia and uremia, organic lesions of the VIII pair of cranial nerves, pregnancy.
    If you have any of the listed diseases, always consult a doctor before using the drug.

    Carefully:
    Myasthenia gravis, parkinsonism, botulism (aminoglcosides can cause a breakdown of the neuromuscular transmission, which leads to further weakening of the skeletal muscles), obliterating endarteritis, heart failure of the Nth degree, chronic renal failure, dehydration, cerebral circulation, tendency to bleeding, elderly and children's age, lactation.
    If you have any of the listed diseases, always consult a doctor before using the drug.

    Pregnancy and lactation:
    In pregnancy streptomycin is contraindicated because it penetrates the placental barrier and can exert nephrotoxic and ototoxic effects on the human fetus.
    In the lactation period (breastfeeding) is applied with caution (streptomycin penetrates into breast milk in low concentrations and is poorly absorbed from the gastrointestinal tract).

    Dosing and Administration:
    Intramuscularly.
    The contents of the vial are dissolved in sterile water for injection or in a 0.9% solution of sodium chloride or in a 0.25-0.5% solution of procaine (Novocaine) at a rate of 4 ml of solvent per gram of streptomycin. The solution is prepared immediately prior to administration.
    Adults: single dose for intramuscular injection - 0.5-1 g, daily - 1-
    2 The maximum daily dose of streptomycin for an adult is 2 g. With poor tolerability, patients with a body weight of less than 50 kg, and those over 60 years of age - a daily dose of 750 mg.
    Children: at the age of 3 months - in a dose of 10 mg / kg / day, at the age of 3 to 6 months - 15 mg / kg / day, from 6 months to 2 years - 20 mg / kg / day, for children up to 13 years and adolescents - 15-20 mg / kg / day, but not more than 500 mg / day - for children under 13 years and 1 g / day for adolescents.
    Maximum doses of streptomycin for children of different ages:
    2-4 years - single dose - 150 mg, daily - 300 mg;
    5-6 years - single dose - 175 mg, daily - 350 mg;
    7-9 years - single dose - 200 mg, daily - 400 mg;
    9-14 years - single dose - 250 mg, daily - 500 mg;
    over 14 years - single 500 mg, daily - 1 g.
    Tuberculosis of the lungs and other organs - a daily dose of 15 mg / kg (but not more than 1 g) is administered 1 time per day, with poor tolerance - in 2 divided doses; duration of treatment
    3 month and more (in parallel with taking other antituberculosis drugs).
    Bacterial endocarditis:
    streptococcal etiology (caused by Streptococcus spp., sensitive to penicillin) - streptomycin is administered in combination with benzylpenicillin for 2 weeks: in the first week - 1 g 2 times a day; during the second week - 500 mg 2 times a day; patients older than 60 years - 500 mg twice a day for 2 weeks;
    enterococcal etiology - streptomycin is administered in combination with benzylpenicillin for 6 weeks: in the first 2 weeks - 1 g 2 times a day; for the next four weeks - 500 mg twice a day (the duration of treatment can be reduced with ototoxicity phenomena).
    Tularemia - 0.5-1 g 2 times a day for 7-14 days until the 5th-7th day of absence of febrile temperature.
    Plague, brucellosis - 1 g 2 times a day for at least 7-10 days.
    With a venereal granuloma,acute bacterial intestinal infections and urinary tract infections - a daily dose is divided into 2-4 of administration, the duration of the course - a minimum of 10 days (not to exceed 14 days).
    With renal failure, the daily dose of streptomycin should be reduced. In case of creatinine clearance from 50 to 60 ml / min, the dose should not exceed 500 mg / day; when creatinine clearance is from 40 to 50 ml / min - no more than 400 mg / day.
    For the patients with arterial hypertension and ischemic heart disease initial dose of 250 mg / day, the dosage is increased with good tolerability.

    Side effects:
    From the nervous system: headache, drowsiness, weakness, peripheral neuritis, facial nerve neuritis (burning sensation in the face or mouth, numbness, tingling), neuromuscular blockade with simultaneous administration with muscle relaxants (difficulty breathing, nocturnal apnea, stopping respiration), neurotoxic action (muscle twitching, paresthesia, epileptic seizures).
    From the senses: ototoxicity (hearing loss, ringing, buzzing or feeling of "stuffiness" in the ears, hearing loss down to irreversible deafness), vestibular and labyrinthine disorders (discoordination, dizziness, nausea, vomiting, instability).
    From the urinary system: nephrotoxicity (significant increase or decrease in frequency of urination, oligurnia, polyuria, thirst, anorexia, nausea, vomiting).
    On the part of the digestive system: nausea, vomiting, diarrhea, impaired liver function (increased activity of "liver" transaminases, hyperbuschrug-binemia).
    Allergic reactions: itching, skin rash, rash, angioedema, fever.
    Local reactions: psyremia and pain at the injection site.
    If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.

    Overdose:
    Symptoms: toxic reactions (hearing loss, ataxia, dizziness, urination disorders, thirst, anorexia, nausea, vomiting, ringing or feeling in the ears, disturbing the breathing until it stops).
    Treatment: for lifting the blockade of the neuromuscular transmission and its consequences - conducting hemodialysis or peritoneal dialysis; taking cholinesterase inhibitors, calcium salts; artificial lung ventilation; other symptomatic and supportive therapy.

    Interaction:
    It is inadmissible to mix in one syringe with antibiotics of the penicillin series and cephalosporins. When used simultaneously with other nephro- and ototoxic drugs (including other aminoglycosides, polymyxinamn, capreomycin), the risk of oto- and nephrotoxic action increases.
    Streptomycin exhibits synergism with simultaneous use with beta-lactamnom antibiotics (penicillins and cephalosporins).
    Streptomycin reduces the effectiveness of antimiasthenic drugs.
    Methoxyflurane increases the risk of streptomycin side effects.
    Preparations for inhalation anesthesia (halogenated hydrocarbons),
    opioid analgesics, transfusion of large amounts of blood with cetrate preservatives as anticoagulants and other drugs that block neuromuscular transmission - with simultaneous application with streptomycin, neuromuscular blockade may be strengthened.
    Intravenous administration of nondomethacin reduces the kidney clearance of streptomycin, increasing the concentration in the blood and increasing T1 / 2.

    Special instructions:
    During the treatment period, it is necessary to monitor the function of the kidneys, the auditory nerve and the vestibular apparatus at least once a week.
    The likelihood of developing nephrotoxicity is higher in patients with impaired renal function, as well as in the administration of high doses or for a long time (this category of patients may require daily monitoring of kidney function).
    When unsatisfactory audiometric tests, the dose of the drug is reduced or discontinued.
    In the absence of positive clinical dynamics should be remembered the possibility of developing resistant microorganisms. In such cases, it is necessary to cancel treatment and begin appropriate therapy.
    Children up to 1 year old streptomycin appoint only for "vital" indications.


    Effect on the ability to drive transp. cf. and fur:During the administration of the drug, care should be taken when driving vehicles, mechanisms and other potentially hazardous activities that require a high concentration of attention and speed of psychomotor reactions.
    Form release / dosage:
    Powder for solution for intramuscular injection 0.5 g, 1 g.
    For 0.5 g and 1 g of active substance in bottles with a capacity of 10 ml or 20 ml.
    1, 5 or 10 bottles with instructions for use are placed in a pack of cardboard.
    50 bottles will be placed in a cardboard box with 10 instructions for use for delivery to hospitals.

    Packaging:
    Powder for solution for intramuscular injection 0.5 g, 1 g.
    For 0.5 g and 1 g of active substance in bottles with a capacity of 10 ml or 20 ml.
    1, 5 or 10 bottles with instructions for use are placed in a pack of cardboard.
    50 bottles will be placed in a cardboard box with 10 instructions for use for delivery to hospitals.

    Storage conditions:
    In a dry place at a temperature of 15 to 25 ° C.
    Keep out of the reach of children.
    Shelf life:
    3 years. Do not use after the expiry date printed on the package. Leave conditions

    Terms of leave from pharmacies:On prescription
    Registration number:LS-002061
    Date of registration:23.11.2010
    The owner of the registration certificate:SYNTHESIS, OJSC SYNTHESIS, OJSC Russia
    Manufacturer: & nbsp
    Representation: & nbspSYNTHESIS JSC Joint-Stock Kurgan Society of Medical Preparations and Products SYNTHESIS JSC Joint-Stock Kurgan Society of Medical Preparations and Products Russia
    Information update date: & nbsp20.08.2015
    Illustrated instructions
      Instructions
      Up